SEC Form 20-F filed by Genenta Science S.p.A.
$GNTA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/29/2023 | $15.00 | Buy | ROTH MKM |
| 7/25/2022 | $25.00 | Buy | H.C. Wainwright |
ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00